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Abstract:	Herein	we	describe	our	full	investigations	into	the	synthesis	of	the	peptide	derived	natural	product	
plantazolicin	A,	a	compound	which	demonstrates	promising	selective	activity	against	the	causative	agent	of	
anthrax	toxicity,	and	its	biosynthetic	precursor	plantazolicin	B.	This	report	particularly	focuses	on	the	
challenging	preparation	of	the	arginine	containing	thiazole	fragment,	including	the	development	of	a	robust,	
high	yielding	procedure	that	avoids	the	use	of	sulfurating	agents.	Extensive	studies	on	the	design	of	a	coherent	
protecting	group	strategy	and	the	establishment	of	a	step	efficient	dicyclization/oxidation	approach	allowed	
high	levels	of	convergence	for	the	construction	of	the	oxazole	fragments.	This	has	led	to	a	unified,	highly	
convergent	synthesis	for	both	plantazolicin	A	and	B.	
Introduction 
The	need	for	new	antibiotics,	especially	those	which	work	by	novel	mechanisms	of	action,	is	undisputed.[1]	The	
rise	of	antibiotic	resistant	bacteria	is	thought,	in	part,	to	have	been	due	to	the	use	of	broad	spectrum	antibiotics	
and	therefore	narrow	spectrum	anti-bacterial	compounds	are	garnering	increased	attention.[1]	Natural	products	
have	proven	to	be	a	significant	source	of	both	chemically	and	mechanistically	diverse	antibiotics.[2]	The	isolation	
of	the	bioactive	molecule	plantazolicin	A	(1)	and	its	biosynthetic	precursor[3]	plantazolicin	B	(2)	was	first	
reported	in	2011	from	the	Bacillus	amyloliquifaciens	FZB42[4],	a	bacterium	which	has	been	recently	reclassified	
as	Bacillus	velezensis	FZB42[5].	These	molecules	both	consist	of	an	unusual	linear	14	amino	acid	sequence	which	
is	highly	modified	to	give	two	polyazole	subunits,	(figure	1),	and	plantazolicin	A	has	been	predicted	to	sit	in	a	
dynamic	hairpin	like	conformation.[6]		
	
Figure	1.	Plantazolicin	A	(1)	and	B	(2)	showing	numbering	of	residues.	
	
It	has	been	observed	that	the	bioactivity	of	these	molecules	is	dependent	on	the	N-terminus	dimethylation,	
with	plantazolicin	A	(1)	showing	selective	and	potent	activity	against	Bacillus	anthracis,	the	causative	agent	of	
anthrax	toxicity[7],	while	biosynthetic	precursor	plantazolicin	B	(2)	exhibits	reduced	biological	activity.[8]	It	is	
thought	that	plantazolicin	A	acts	by	causing	membrane	depolarisation	and	lysis	of	B.	anthracis	selectively	by	
taking	advantage	of	a	locally	weakened	cell	membrane.[7a]	Additionally,	while	some	truncated	analogues	of	the	
left	hand	side	of	1	have	shown	respectable	activity	against	B.	anthracis,	they	also	exhibit	reduced	selectivity,	
with	their	activity	thought	to	occur	by	a	different	mechanism.[7a,9]		
The	promising	bioactivity	of	plantazolicin	A,	along	with	its	novel	and	challenging	structure	has	led	to	significant	
interest	into	the	synthesis	of	these	molecules.	To	date,	our	recently	communicated	synthesis	of	plantazolicin	A	
(1)[10]	is	the	second	of	three	reported	total	syntheses	of	this	natural	product	and	the	only	report	of	the	synthesis	
and	full	characterisation	of	biological	precursor	plantazolicin	B	(2).	Süssmuth	et	al.	reported	the	synthesis	of	
plantazolicin	A	(1)	in	2013.[11]	Moody	et	al.	have	recently	reported	an	elegant	total	synthesis	of	plantazolicin	A	
(1)	based	on	rhodium-catalysed	carbene	N-H	insertion[6].	The	synthesis	and	biological	evaluation	of	shortened	
plantazolicin	analogues,	and	their	use	to	further	elucidate	the	biosynthesis	of	the	natural	products,	has	also	
been	described	by	both	the	Mitchell[3c,9]	and	Süssmuth[3b]	groups.	Herein	we	fully	disclose	our	ultimately	
successful	endeavours	towards	these	molecules.	
	
Synthetic	strategy	
While	there	are	many	potential	approaches	to	the	synthesis	of	these	molecules,	in	terms	of	convenience	and	
efficiency,	careful	planning	is	important	to	allow	the	exploitation	of	affordable	and	readily	available	building	
blocks.	Accordingly,	our	synthetic	endeavours	were	focused	on	the	use	of	natural	amino	acids	as	building	blocks	
where	possible.	The	initial	synthetic	strategy	for	the	synthesis	of	plantazolicin	A	(1)	and	B	(2)	was	designed	to	be	
as	convergent	as	possible,	with	the	natural	products	being	split	into	two	pentacycles	by	disconnecting	at	the	
hinge	point	between	the	two	isoleucine	residues.	It	was	imagined	that	it	would	be	necessary	to	form	the	
sensitive	oxazolidine	ring	after	the	final	coupling	to	avoid	its	hydrolysis.	As	the	mechanism	of	the	dehydrative	
cyclization	is	invertive,	this	necessitates	the	incorporation	of	a	L-allo-threonine	residue	at	this	position.	For	the	
left	hand	side	it	was	hoped	that	the	arginine	containing	fragment,	which	differentiates	between	plantazolicin	A	
(1)	and	B	(2)	could	be	installed	in	an	advanced	stage	to	ensure	maximum	convergence	between	the	two	
syntheses.	Our	protecting	group	strategy	was	based	on	having	protecting	groups	on	the	guanidine	moiety	of	the	
arginine	residue	and	the	C-terminus	which	could	be	simultaneously	removed	(carboxyl	benzyl	(Cbz)	and	benzyl	
(Bn)),	while	the	N-terminus	was	orthogonally	protected	to	allow	synthesis	of	plantazolicin	A	(1)	and	B	(2)	from	a	
common	route.	It	was	envisaged	that	the	two	thiazole	rings	could	be	built	by	using	modified	Hantzsch	thiazole	
syntheses,	and	that	oxazole	rings	could	be	assembled	through	iterative	amino	acid	couplings	followed	by	
cyclization	and	oxidation	using	the	methodology	of	Wipf	and	Williams[12]	(scheme	1).	
	Scheme	1.	Initial	retrosynthetic	strategy	for	the	synthesis	of	plantazolicin	A	(1)	and	B	(2).	
	
Results	and	Discussion	
Synthesis	of	LHS	fragments	
Synthesis	of	arginine	thiazole	fragments.	One	of	the	most	challenging	sections	of	plantazolicin	proved	to	be	the	
synthesis	of	the	two	coupling	partners	which	contained	arginine	derived	thiazoles,	6	and	7.	Originally	we	had	
decided	to	simply	employ	a	modified	Hantzsch	thiazole	synthesis[13]	for	the	formation	of	the	desired	
heterocycle.	Differentially	protected	arginine	12	was	chosen	as	the	starting	material	as	it	is	commercially	
available,	but	should	allow	for	the	selective	deprotection	of	the	alpha	nitrogen	to	allow	N-dimethylation	to	give	
access	to	6,	the	required	coupling	partner	for	plantazolicin	A,	or	left	with	the	Boc-protected	alpha	nitrogen	7	for	
plantazolicin	B	(scheme	2).		
	
Scheme	2.	Initial	retrosynthesis	for	arginine	derived	thiazoles	6	and	7.	
	The	route	began	with	the	amidation	of	Boc-Arg(Cbz)2-OH	12	with	the	crude	amide	being	directly	converted	to	
the	thioamide	using	the	sulfurating	agent	Belleau’s	reagent[14]	in	an	acceptable	77%	yield.	The	key	modified	
Hantzch	thiazole	formation[13]	was	then	carried	out	to	afford	thiazole	7	in	a	modest	33%	yield.	Pleasingly,	it	was	
found	that	the	alpha	nitrogen	of	the	arginine	residue	could	be	deprotected	using	trifluoroacetic	acid	(TFA)	and	
although	N-methylation	was	at	first	unsuccessful	when	attempted	using	the	Eschweiler-Clarke	reaction[15],	it	
was	found	that	reductive	amination	could	be	carried	out	using	sodium	cyanoborohydride[16]	to	afford	dimethyl	
arginine	thiazole	6	in	54%	yield	(scheme	3).	However,	the	overall	yield	of	only	25%	for	thiazole	7	was	limiting,	
and	additionally	it	was	found	that	the	yield	of	the	thiazole	formation	tended	to	be	variable	when	it	was	carried	
out	on	scale,	necessitating	an	alternative	approach	for	thiazole	7.	
	
Scheme	3.	Modified	Hantzsch	synthesis	of	arginine	thiazoles	6	and	7.	Reagents	and	conditions:	a)	i.	
isobutylchloroformate,	NMM,	THF,	-20	°C,	10	min,	ii.	NH4OH	(35%	in	H2O),	0	°C,	5.5	h;	b)	Belleau's	reagent,	THF	
0	°C	-	rt,	2.5	h,	77%;	c)	ethyl	bromopyruvate,	KHCO3,	DME,	-15	°C,	5	min	then	trifluoroacetic	anhydride,	2,6-
lutidine,	DME,	-15	°C,	4	h,	33%;	d)	i.	TFA,	CH2Cl2,	rt,	3.5	h,	ii.	37%	aq.	CH2O,	CH3OH,	rt,	40	min	then	NaBH3CN,	rt,	
14.5	h,	54%.	NMM	=	N-methylmorpholine.	
	
The	condensation	of	cysteine	ethyl	ester	(22)	with	an	amino	acid	derived	aldehyde[17]	allows	the	formation	of	
thiazolidines	from	amino	acid	derived	precursors	without	requiring	the	use	of	unpleasant	sulfurating	reagents.	
It	was	envisaged	that	if	arginine	derived	aldehyde	23	could	be	accessed,	this	would	provide	a	rapid	access	to	
thiazole	7	from	readily	available	starting	materials	(scheme	4).	
	
Scheme	4.	Alternative	retrosynthesis	for	thiazole	7.	
	Straightforward	coupling	of	differentially	protected	arginine	12	with	N,O-dimethylhydroxylamine	25		afforded	
amide	26,	which	could	then	be	reduced	to	the	required	amino	acid	derived	aldehyde	quantitatively.	The	crude	
aldehyde	was	directly	coupled	with	cysteine	ethyl	ester	hydrochloride	22	in	biphasic	solution	with	sub-
stoichiometric	potassium	bicarbonate[17a],	to	afford	the	thiazolidine	24.	This	could	then	be	oxidised	using	
manganese	dioxide,	to	reproducibly	afford	thiazole	7	in	four	steps	(three	purifications)	and	an	overall	yield	of	
52%	(scheme	5).	
	
Scheme	5.	Alternative	synthesis	of	thiazole	7.	Reagents	and	conditions:	a)	CH3ONHCH3.HCl	25,	NiPr2Et,	HOBt,	
EDCI,	CH2Cl2,	rt,	16	h,	96%,	b)	i.	DIBAL-H,	CH2Cl2,	-78	°C,	40	min,	ii.	Cys-OEt.HCl	22,	KHCO3,	MeOH/toluene/H2O,	
rt,	15	h,	81%;	c)	MnO2,	toluene,	80	°C,	24	h,	67%.	DIBAL-H	=	diisobutylaluminium	hydride.	
	
As	the	synthesis	progressed,	it	was	found	that	the	hydrolysis	of	the	ethyl	ester	of	6	and	7	to	afford	the	free	acid	
was	problematic,	with	significant	amounts	of	degradation	being	seen	under	a	range	of	conditions	for	the	
hydrolysis.	To	avoid	this	problem,	cysteine	methyl	ester	hydrochloride	27	was	used	as	the	aldehyde	coupling	
partner	in	the	established	route	to	afford	methyl	ester	protected	thiazoles	28	and	29	(scheme	6).	
	
Scheme	6.	Synthesis	of	arginine	thiazole	methyl	esters	28	and	29.	Reagents	and	conditions:	a)	i.	DIBAL-H,	CH2Cl2,	
-78	°C,	50	min,	ii.	Cys-OMe.HCl	27,	KHCO3,	MeOH/toluene/H2O,	rt,	15.5	h,	75%;	b)	MnO2,	toluene,	80	°C,	19.5	h,	
57%;	c)	i.	TFA,	CH2Cl2,	rt,	5	h,	ii.	37%	aq.	CHO,	CH3OH,	rt,	1	h	then	NaBH3CN,	rt,	18	h,	52%.	
	
Additionally,	as	the	protecting	group	strategy	developed,	it	became	necessary	to	have	the	arginine	guanidine	
nitrogens	protected	using	tert-butyloxycarbonyl	protecting	group.	Initially	this	was	accomplished	by	removing	
the	nitrogen	protecting	groups	from	the	four	synthesised	thiazoles,	6,	7,	28	and	29,	and	directly	reprotecting	
them	using	di-tert-butyl	dicarbonate	and	diisopropyethylamine	to	afford	the	di-	(31	and	32)	or	tri-	(33	and	34)	
Boc	protected	thiazoles	in	eight	or	six	steps	respectively	(scheme	7).		
	
Scheme	7.	Swapping	protection	on	arginine	thiazoles.	Reagents	and	conditions:	a)	i.	PdCl2,	H2,	MeOH,	45	min	
(31	and	34)/50	min	(32)/30	min	(33),	ii.	Boc2O,	NiPr2Et,	CH2Cl2,	rt,	4	days	(31,	32	and	34)/	6	days	(33),	31	=	86%,	
32	=	24%,	33	=	87%,	34	=	87%.	
	
A	more	step	efficient	method	for	the	preparation	of	the	guanidine	Boc	protected	thiazoles	was	next	attempted,	
starting	from	carboxybenzyl	arginine	35.	The	free	acid	was	converted	to	the	methyl	ester	and	the	crude	ester	
Boc	protected	as	previously	established.	This	afforded	a	separable	4.7:1	ratio	of	the	Nδ,Nωʹ	(31a)	and	Nω,Nωʹ	
(31b)	protected	isomers	in	overall	57%	yield.	Both	isomers	could	then	be	progressed	through	to	the	thiazole.	It	
was	found	that	esters	36	could	be	reduced	to	the	required	aldehyde	without	over-reduction	to	the	
corresponding	alcohol,	then	directly	used	in	the	thiazolidine	formation	as	previously	employed.	However,	it	was	
found	that	removal	of	the	Cbz	group	from	Nα	with	retention	of	the	Boc	protection	on	the	guanidine	
functionality	was	challenging.	When	hydrogenation	of	thiazole	37a	was	attempted	using	palladiumII	chloride,	
buffered	with	potassium	carbonate	to	ensure	retention	of	the	Boc	protection,	only	a	small	amount	of	the	
desired	Cbz	deprotected	product	was	formed,	which	could	then	be	N-dimethylated	as	previously	to	afford	only	
18%	of	31a,	with	42%	of	starting	material	37a	also being	recovered.	This	indicated	that	the	Cbz	deprotection	
was	in	fact	mediated	by	the	acid	produced	when	palladiumII	chloride	was	reduced	to	palladium0,	rather	than	
solely	by	hydrogenation.	
When	palladiumII	chloride	was	used	unbuffered,	while	the	Nα	was	fully	deprotected,	the	Boc	groups	were	also	
partially	deprotected.	While	pleasingly	it	was	seen	that	controlling	the	pH	of	the	reaction	mixture	allowed	for	
the	selective	N-methylation	at	Nα,	this	did	necessitate	an	additional	Boc	reprotection	step	to	afford	the	two	
differently	protected	isomers	of	thiazole	31	(scheme	8).	
Scheme	8.	Alternative	protecting	group	strategy	for	arginine	thiazoles.	Reagents	and	conditions:	a)	i.	
Si(CH3)3Cl,	MeOH,	rt,	18.5	h,	ii.	Boc2O,	NiPr2Et,	MeOH,	CH2Cl2,	rt,	6	days,	47%	(36a)	and	10%	(36b);	b)	
i.	DIBAL-H,	CH2Cl2,	-78	°C,	3	h	10	min	(38a)/3	h	(38b),	ii.	Cys-OMe.HCl	27,	KHCO3,	toluene/H2O/MeOH	
(36b	only),	rt,	21	h	(38a)/22	h	(38b),	38a	=	64%,	38b	=	54%;	c)	MnO2,	toluene,	80	°C,	24	h	(37a)/20	h	
(37b),	37a	=	54%,	37b	=	17%;	d)	i.	K2CO3,	PdCl2,	H2,	MeOH,	rt,	3	h,	ii.	37%	aq.	CHO,	MeOH,	rt,	1	h	then	
NaBH3CN,	rt,	20.5	h,	18%	(31a)	and	42%	(37a);	e)	i.	PdCl2,	H2,	MeOH,	rt,	1	h,	ii.	37%	aq.	CH2O,	MeOH,	
rt,	1	h	then	NaBH3CN,	rt,	20.5	h,	iii.	Boc2O,	NiPr2Et,	MeOH,	CH2Cl2,	rt,	4	days,	36%	(31a)	and	23%	
(31b).	
	
Boc-N-Arg(Boc2)-OH	39	is	commercially	available,	which	meant	that	both	the	methyl	(33)	and	ethyl	
(34)	esters	of	the	tri-boc	thiazole	could	be	synthesised	in	just	four	steps	(three	purifications)	by	the	
established	route.	The	N-dimethyl	thiazoles	could	then	be	accessed	by	Boc	deprotection,	reductive	
amination	at	the	Nα	position	and	Boc	reprotection.	Global	Boc	deprotection	was	first	attempted	
using	trifluoroacetic	acid,	which	afforded	an	11%	yield	of	the	desired	dimethyl	thiazole	31a	after	
reductive	amination	and	reprotection.	Pleasingly,	however,	it	was	found	that	deprotection	using	
anhydrous	hydrochloric	acid	followed	by	reductive	amination	and	reprotection	afforded	a	52%	yield	
of	thiazole	31	as	a	separable	35:17	(a:b)	mixture	of	the	two	protected	isomers	(scheme	9).	
	
Scheme	9.	Synthesis	of	arginine	thiazoles	from	tri-Boc	arginine.	Reagents	and	conditions:	a)	
CH3ONHCH3.HCl	25,	NiPr2Et,	HOBt,	EDCI,	CH2Cl2,	rt,	16	h,	99%,	b)	i.	DIBAL-H,	CH2Cl2,	-78	°C,	1	h,	ii.	
Cys-OMe.HCl	27	(41)	or	Cys-OEt.HCl	22	(42),	KHCO3,	MeOH/toluene/H2O,	rt,	41.5	h	(41)/19	h	(42),	41	
=	78%,	42	=	73%;	c)	MnO2,	toluene,	80	°C,	15	h	(33)/21	h	(34),	33	=	48%,	34	=	59%;	d)	i.	TFA,	CH2Cl2,	
rt,	1	h,	ii.	37%	aq.	CH2O,	CH3OH,	rt,	1.5	h	then	NaBH3CN,	rt,	20	h,	iii.	Boc2O,	NiPr2Et,	rt,	4	days,	11%	
(31a);	e)	i.	HCl,	1,4-dioxane,	rt,	1	h,	ii.	37%	aq.	CH2O,	CH3OH,	rt,	1	h	then	NaBH3CN,	rt,	15.5	h,	iii.	
Boc2O,	NiPr2Et,	CH2Cl2,	rt,	4	days,	35%	(31a)	and	17%	(31b).	HOBt	=	1-hydrobenzotriazole,	EDCI	=	N-
(3-dimethylaminopropyl)-Nʹʹ-ethyl-carbodiimide	hydrochloride.	
	
In	an	effort	to	develop	a	more	step	efficient	approach	to	the	N-dimethyl	thiazoles,	the	preparation	
of	protected	N-dimethyl	arginine	43	was	next	attempted.	Reductive	amination	then	protection	of	
the	free	base	of	arginine	methyl	ester	hydrochloride	44	resulted	in	a	low	5%	yield	of	the	desired	
product	43a.	Pleasingly	however	arginine	45	could	be	Nα-dimethylated	by	a	literature	procedure[18],	
the	acid	esterified	and	Boc	protection	carried	out	to	afford	a	62%	yield	of	43	as	a	separable	2.1:1	
(a:b)	mixture	of	the	two	regioisomers.	It	was	found	that	43a	could	be	reduced,	coupled	with	cysteine	
methyl	ester	hydrochloride	27	and	oxidised	to	afford	thiazole	31a	in	14%	yield	(scheme	10).	While	
this	route	required	one	less	step	than	that	of	scheme	9,	the	overall	yield	was	significantly	lower	(6%	
vs	13%	31a	and	6%	31b)	so	it	was	decided	to	use	the	route	from	Boc-N-Arg(Boc2)-OH	39	for	the	
synthesis	of	both	the	target	thiazoles.	
	
Scheme	10.	Direct	synthesis	of	dimethyl	arginine	thiazole	31a.	Reagents	and	conditions:	a)	i.	
Ambersep®	900-OH,	MeOH,	rt,	5	min,	ii.	CH2O,	MeOH,	rt,	1	h	40	min	then	NaBH3CN,	rt,	18	h,	iii.	
Boc2O,	NiPr2Et,	MeOH,	CH2Cl2,	rt,	7	days,	5%	(43a);	b)	i.	37%	aq.	CHO,	NaBH3CN,	NaOAc,	H2O,	rt,	
16.5	h,	ii.	Si(CH3)3Cl,	MeOH,	rt,	18	h,	iii.	Boc2O,	NiPr2Et,	MeOH,	CH2Cl2,	rt,	13	days,	42%	(43a)	and	20%	
(43b);	c)	i.	DIBAL-H,	CH2Cl2,	-78	°C,	1	h,	ii.	Cys-OMe.HCl	27,	KHCO3,	toluene/H2O,	rt,	18	h,	iii.	MnO2,	
toluene,	80	°C,	23	h,	14%.	
	
Synthesis	of	threonine	thiazole	fragment.	Known	threonine	derived	thiazole	11[19]	was	obtained	
from	Boc-threonine	13	by	the	same	approach	as	was	applied	to	the	synthesis	of	the	arginine	
thiazoles	to	afford	11	in	42%	overall	yield	(scheme	11).	
	
Scheme	11.	Synthesis	of	threonine	thiazole	11.	Reagents	and	conditions:	a)	i.	2,2-dimethoxypropane,	
PPTS,	THF,	reflux,	15	h,	ii.	CH3ONHCH3.HCl	25,	NiPr2Et,	HOBt,	EDCI,	CH2Cl2,	rt,	21	h,	49%;	b)	i.	
CH3ONHCH3.HCl	25,	NiPr2Et,	HOBt,	EDCI,	CH2Cl2,	rt,	22	h,	ii.	2,2-dimethoxypropane,	PPTS,	THF,	reflux,	
18	h,	86%;	c)	i.	DIBAL-H,	CH2Cl2,	-78	°C,	30	min,	ii.	Cys-OEt.HCl	22,	KHCO3,	toluene/H2O/MeOH,	rt,	
15	h,	83%;	d)	MnO2,	toluene,	80	°C,	24	h,	59%.	PPTS	=	para-toluene	sulphonate.	
	
Synthesis	of	tri-azole.	The	route	to	tri-azole	8	started	with	the	hydrolysis	of	the	ethyl	ester	of	
threonine	thiazole	11	using	lithium	hydroxide	before	it	was	coupled	with	threonine	methyl	ester	
hydrochloride	15	to	afford	48	in	57%	yield.	Cyclization	was	effected	using	the	fluorinating	reagent	
Deoxo-Fluor®	and	oxidation	with	bromotrichloromethane	(BrCCl3)	and	1,8-diazabicycloundec-7-ene	
(DBU)	according	to	a	one-pot	method	of	Wipf	and	Williams[12]	to	afford	dicycle	49	in	43%	yield.	The	
synthesis	of	di-cycle	49	in	54%	overall	yield	from	48	using	flow	chemistry	has	been	previously	
reported	by	this	group.[20]	Di-cycle	49	was	then	coupled	with	Boc	deprotected	threonine-isoleucine	
dipeptide	50	before	cyclization	and	oxidation	to	afford	a	modest	15%	yield	of	tri-azole	8	(scheme	
12).	The	final	oxidation	was	also	attempted	using	manganese	dioxide,	however	this	only	resulted	in	
partial	conversion	to	the	desired	product,	even	with	large	excesses	of	oxidant.	
	
Scheme	12.	Linear	synthesis	of	tri-azole	8.	Reagents	and	conditions:	a)	i.	LiOH.H2O,	THF/H2O,	0	°C	–	
rt,	13	h,	ii.	Thr-OMe.HCl	15,	NiPr2Et,	HOBt,	EDCI,	CH2Cl2,	rt,	17	h,	57%;	b)	Deoxo-Fluor®,	CH2Cl2,	-20	°C,	
2	h	then	DBU,	BrCCl3,	-20	°C	–	0	°C,	60	h,	43%;	c)	Ile-OMe.HCl	14,	NiPr2Et,	HOBt,	EDCI,	CH2Cl2,	rt,	17	h,	
99%;	d)	LiOH.H2O,	THF/H2O,	0	°C	–	rt,	18	h;	e)	anhydrous	HCl,	1,4-dioxane,	rt,	45	min;	f)	NiPr2Et,	
HOBt,	EDCI,	CH2Cl2,	rt,	19	h,	31%	(3	steps);	g)	Deoxo-Fluor®,	CH2Cl2,	-20	°C,	2	h	then	DBU,	BrCCl3,	-
20	°C	–	0	°C,	48	h,	15%.	
	
In	order	to	facilitate	a	more	convergent	approach	to	tri-azole	8	it	was	next	decided	to	determine	
whether	the	two	cyclization	and	oxidation	steps	could	be	carried	out	concurrently.	Tripeptide	52	was	
synthesised	in	80%	yield	by	straightforward	peptide	couplings	using	EDCI	and	HOBt	(see	supporting	
information).	This	was	coupled	with	threonine	thiazole	11	to	give	cyclization	precursor	53.	It	was	
found	that	by	increasing	the	reaction	time	and	the	equivalents	of	BrCCl3	and	DBU	used	the	
dicyclization	and	oxidation	could	be	affected	in	64%	yield	(scheme	13).	
	
Scheme	13.	Convergent	synthesis	of	tri-azole	8.	Reagents	and	conditions:	a)	LiOH.H2O,	MeOH/H2O,	
rt,	3	h;	b)	anhydrous	HCl,	1,4-dioxane,	rt,	30	min;	c)	NiPr2Et,	HOBt,	EDCI,	CH2Cl2,	rt,	17.5	h,	71%;	d)	
Deoxo-Fluor®,	CH2Cl2,	-20	°C,	2.5	h	then	DBU,	BrCCl3	(portionwise),	-20	°C	–	0	°C,	110	h,	64%.	
	
Completion	of	LHS	fragments.	Next	attention	turned	to	the	completion	of	the	two	left	hand	side	
fragments	54	and	55.	While	the	N-Boc	deprotections	were	routinely	effected	using	anhydrous	
hydrochloric	acid	in	dioxane,	it	was	found	that	the	addition	of	water	to	the	reaction	mixture	allowed	
the	simultaneous	removal	of	the	Boc	protection	and	the	acetal	from	8,	whereas	when	anyhydrous	
HCl	was	used	only	the	Boc	protection	was	lost.	It	was	found	that	the	methyl	esters	of	31	and	33	
could	be	carefully	hydrolysed	at	low	temperature	and	the	deprotected	molecules	coupled	using	1-
[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium	3-oxide	hexafluorophosphate	
(HATU)	and	diisopropylethylamine	to	afford	cyclization	precursors	56	and	57.	The	established	
cyclization/oxidation	conditions	were	then	employed	to	afford	the	pentacycles	54	and	55	with	
overall	yields	of	8%	and	12%	respectively	for	the	longest	linear	pathways	(scheme	14).	
Scheme	14.	Completion	of	left	hand	fragments	54	and	55.	Reagents	and	conditions:	a)	LiOH.H2O,	
MeOH/H2O,	0	°C,	1.5	h;	b)	HCl	(dioxane/H2O),	1,4-dioxane,	rt,	1	h;	c)	HATU,	NiPr2Et,	CH2Cl2/DMF,	0	°C	
-	rt,	22	h,	56	=	61%,	57	=	66%;	d)	Deoxo-Fluor®,	CH2Cl2,	-20	°C,	2	h	then	DBU,	BrCCl3,	-20	°C	–	0	°C,	
20	h	(54)/	15	h	(55),	54	=	69%,	55	=	92%.	DMF	=	N,N-dimethylformamide.	
	
Synthesis	of	RHS	fragment	
Synthesis	of	tetraoxazole	fragment.	The	preparation	of	right	hand	side	pentacycle	5	began	with	the	
preparation	of	tetracycle	9.	This	synthesis	started	by	the	coupling	of	Boc-protected	isoleucine	16	
with	serine	methyl	ester	hydrochloride	17	followed	by	cyclization	and	oxidation	to	install	the	first	
ring,	with	the	remaining	three	rings	being	installed	iteratively	by	the	same	process,	affording	
tetracycle	9	in	eleven	steps	and	10%	overall	yield	(scheme	15).	
	
With	the	synthesis	of	tetraoxazole	9	successfully	achieved,	attention	turned	to	whether	this	route	
could	be	improved	by	the	use	of	multiple	cyclizations	in	one	step.	However	it	was	found	that	the	
synthesis	of	the	cyclization	precursors	limited	the	number	of	rings	we	could	attempt	to	form	at	once.	
While	tripeptide	65	and	diserine	66	could	be	obtained	using	standard	solution	phase	coupling	
conditions,	all	attempts	at	gaining	access	to	tri-	or	tetraserine	containing	molecules	were	
unsuccessful,	which	could	in	part	be	due	to	the	high	polarity	of	these	compounds	and	resulting	
solubility	problems	in	organic	solvents.	When	tripeptide	65	was	submitted	to	the	
cyclization/oxidation	conditions	it	was	found	that	under	optimised	conditions	only	23%	dioxazole	
product	61	was	formed,	with	the	major	product	(61%)	being	the	dicyclised	but	only	mono-oxidised	
product	67,	which	meant	that	the	most	efficient	synthesis	of	dioxazole	61	would	be	the	linear	
approach	of	scheme	15.		
	
Scheme	15.	Linear	synthesis	of	tetraoxazole	9.	a)	Ser-OMe.HCl	17,	NiPr2Et,	HOBt,	EDCI,	CH2Cl2,	20	h,	
91%;	b)	Deoxo-Fluor®,	CH2Cl2,	-20	°C,	30	min	then	BrCCl3,	DBU,	-20	°C	–	3	°C,	8	h,	81%;	c)	i.	LiOH.H2O,	
THF/MeOH/H2O,	0	°C	–	rt,	18	h,	ii.	Ser-OMe.HCl	17,	NiPr2Et,	HOBt,	EDCI,	CH2Cl2,	20	h,	84%;	d)	Deoxo-
Fluor®,	CH2Cl2,	-20	°C,	30	min	then	BrCCl3,	DBU,	-20	°C	–	3	°C,	8	h,	78%;	e)	i.	LiOH.H2O,	
THF/MeOH/H2O,	0	°C,	3	h,	ii.	Ser-OMe.HCl	17,	NiPr2Et,	HOBt,	EDCI,	CH2Cl2,	20	h,	79%;	f)	Deoxo-Fluor®,	
CH2Cl2,	-20	°C,	30	min	then	BrCCl3,	DBU,	-20	°C	–	3	°C,	8	h,	73%;	g)	i.	LiOH.H2O,	THF/MeOH/H2O,	0	°C	
–	rt,	8	h,	ii.	Ser-OMe.HCl	17,	NiPr2Et,	HOBt,	EDCI,	CH2Cl2,	20	h,	71%;	d)	Deoxo-Fluor®,	CH2Cl2,	-20	°C,	
30	min	then	BrCCl3,	DBU,	-20	°C	–	3	°C,	6.5	h,	53%.	
	
The	second	dicyclization	precursor	68	was	synthesised	by	either	coupling	61	and	diserine	66,	or	by	
the	less	convergent	coupling	of	dioxazole	serine	64	with	Ser-OMe.HCl	17	(see	supporting	
information).	Pleasingly,	dicyclization/oxidation	of	68	proceeded	in	77%	yield	to	afford	tetraoxazole	
9	in	overall	47%	yield	from	61, which	is	a	marked	improvement	on	the	linear	conversion	of	61	to	9	
which	had	an	overall	yield	of	22%,	so	this	approach	was	incorporated	into	the	final	route	(scheme	
16).	
	
Scheme	16.	Convergent	synthesis	of	tetraoxazole	9.	Reagents	and	conditions:	a)	i.	LiOH.H2O,	
THF/MeOH/H2O,	0	°C,	2	h	45	min,	ii.	Ser-OMe.HCl	17,	NiPr2Et,	HOBt,	EDCI,	CH2Cl2,	20	h,	74%;	b)	
Deoxo-Fluor®,	CH2Cl2,	-20	°C,	1	h	45	min	then	BrCCl3,	DBU,	-20	°C	-	-10	°C,	30	min,	-10	°C	–	0	°C,	6	h,	
23%	(61)	and	61%	(67);	c)	Ser-OMe.HCl	17,	NiPr2Et,	HOBt,	EDCI,	CH2Cl2,	20	h,	88%;	d)	.	LiOH.H2O,	
THF/MeOH/H2O,	0	°C	-	rt,	2	h;	e)	anhydrous	HCl,	1.4-dioxane,	0	°C	-	rt,	3.5	h;	f)	NiPr2Et,	HOBt,	EDCI,	
CH2Cl2,	20	h,	61%;	g)	Deoxo-Fluor®,	CH2Cl2,	-20	°C,	30	min	then	BrCCl3,	DBU,	-20	°C	–	0	°C,	8	h,	77%.	
	
It	was	found	that	tetraoxazole	9	was	very	poorly	soluble,	which	proved	problematic	when	the	
hydrolysis	of	the	ester	of	this	compound	was	attempted	to	enable	progression,	which	was	also	
observed	by	Süssmuth	et	al.	for	a	similar	intermediate	in	their	work	towards	plantazolicin	A	(1).[11]	To	
try	to	avoid	this	problem,	tetraoxazoles	with	ethyl	ester	70	and	benzyl	ester	71	protection	were	
obtained	from	trioxazole	63	(scheme	17).	
	
Scheme	17.	Synthesis	of	alternatively	protected	tetraoxazoles	70	and	71.	Reagents	and	conditions:	
a)	i.	LiOH.H2O,	THF/MeOH/H2O,	0	°C	–	rt,	26	h,	ii.	Ser-OEt.HCl	74	(72)/Ser-OBn.HCl	75	(73),	NiPr2Et,	
HOBt,	EDCI,	CH2Cl2,	20	h,	72	=	90%,	73	=	84%;	b)	Deoxo-Fluor®,	CH2Cl2,	-20	°C,	30	min	(70)/45	min	
(71)	then	BrCCl3,	DBU,	-20	°C	–	0	°C,	20	h,	70	=	48%,	71	=	83%.	
Deprotection	of	the	three	tetraoxazoles	was	then	attempted.	Through	use	of	high	temperatures	and	
mixed	solvent	systems	it	was	found	that	both	methyl	ester	9	and	ethyl	ester	70	could	be	
deprotected	using	lithium	hydroxide,	with	methyl	ester	9	being	slightly	higher	yielding	in	initial	tests,	
and	was	therefore	carried	forward	(scheme	18).	Multiple	attempts	at	removing	the	benzyl	ester	of	
71,	both	by	hydrolysis	and	hydrogenation	were	unsuccessful,	so	this	route	was	abandoned.	
	
Scheme	18.	Deprotection	of	tetraoxazoles	9	and	70.	Reagents	and	conditions:	a)	9	–	LiOH.H2O,	
THF/MeOH/H2O,	0	°C	–	rt,	22	h,	62%*/70	–	LiOH.H2O,	CCl3H/MeOH/H2O,	50	°C	–	55	°C,	19	h,	56%*.	
*crude	yields.	
	
Due	to	uncertainty	over	our	overall	protecting	group	strategies	methoxy-	(77),	trimethylsilyl-	(TMSE	-	
78)	and	benzyl	(10)	esters	of	the	required	L-allo-threonine-phenylalanine	dipeptide	were	synthesised	
to	help	establish	what	protecting	group	was	most	appropriate	for	the	C-terminus	(scheme	19).	
	
Scheme	19.	Synthesis	of	C-terminus	dipeptides.	Reagents	and	conditions:	a)	i.	NaHCO3,	H2O,	rt,	
15	min	then	Boc2O,	MeOH,	rt,	13.5	h	(77)/13	h	(10),	ii.	Phe-OMe.HCl	82	(77)/Phe-OBn.HCl	19	(10),	
NiPr2Et,	HOBt,	EDCI,	CH2Cl2,	20	h,	77	=	79%,	10	=	88%;	b)	HOCH2CH2Si(CH3)3,	EDCI,	DMAP,	CH2Cl2,	0	°C	
-	rt,	18	h,	74%;	c)	anhydrous	HCl,	1,4-dioxane,	rt,	2	h;	d)	NaHCO3,	H2O,	rt,	15	min	then	Boc2O,	MeOH,	
rt,	15.5	h;	e)	HATU,	NiPr2Et,	CH2Cl2,	0	°C	–	rt,	16	h,	81%.	DMAP	=	4-dimethylaminopyridine.	
	
These	dipeptides	were	then	coupled	using	HATU	to	the	tetraoxazole	9	to	give	three	potential	right	
hand	side	coupling	partners,	5,	83	and	84.	Benzyl	ester	5	was	then	dehydratively	cyclised	to	the	
oxazoline	85	using	diethylaminosulfur	trifluoride	(DAST)	in	a	modest	39%	yield.	It	was	seen	that	the	
key	coupling	constant	of	the	doublet	of	5-MeOxl13-C4H	(4.32	ppm,	J	=	7.6	Hz)	correlated	well	to	this	
coupling	in	the	natural	product	(4.23	ppm,	J	=	7.6	Hz)[4a],	which	was	a	reassuring	preliminary	
indication	that	the	cyclodehydration	was	proceeding	with	inversion,	consistent	with	an	SN2-like	ring	
closing	mechanism	(scheme	20).	This	was	supported	by	the	fact	that	when	86	was	synthesised	via	an	
analogous	route	from	natural	L-threonine	the	coupling	constant	was	considerably	larger	(4.78	ppm,	J	
=	10.0	Hz)	(see	supporting	information).	
	
Scheme	20.	Synthesis	of	right	hand	side	coupling	partners,	showing	key	1H	NMR	coupling	constant.	
Reagents	and	conditions:	a)	LiOH.H2O,	MeOH/CHCl3/H2O,	55	°C-65	°C,	7	h	–	2	days;	b)	anhydrous	HCl,	
1,4-dioxane,	0	°C	–	rt,	30	min;	c)	NiPr2Et,	HOBt,	EDCI,	CH2Cl2,	DMF	(83	only)	20	h,	83	=	9%,	5	=	37%;	d)	
HATU,	NiPr2Et,	CH2Cl2/DMF,	0	°C	–	rt,	20	h	(5)/18	h	(84),	5	=	60%,	84	=	77%;	e)	DAST,	CH2Cl2,	-78	°C,	
1	h	then	K2CO3,	-78	°C,	15	min	then	rt,	30	min,	39%	(85).	
	
Coupling	and	completion	
Model	coupling	and	deprotections.	With	the	synthesis	of	the	two	left	hand	side	fragments	54	and	
55	and	the	right	hand	side	with	three	different	forms	of	C-terminus	protection	5,	83	and	84	
successfully	completed,	next	it	was	desirable	to	establish	suitable	conditions	for	the	end	game	of	the	
route	using	a	model,	before	attempting	it	on	the	actual	substrates.		
Tri-azole	8	and	dipeptide	10	were	deprotected	using	the	established	conditions	before	coupling	with	
HATU	to	afford	the	coupled	product	87	in	a	modest	38%	yield.	The	threonine	residue	of	coupled	
model	87	was	then	dehydratively	cyclised	using	Deoxo-Fluor®,	as	this	had	been	reported	to	be	more	
effective	at	cyclising	threonine	residues	than	DAST[12],	affording	the	oxazoline	88	in	74%	yield.	
Attention	then	turned	to	the	deprotection	of	the	C-	and	N-	termini	where	it	was	found	that	it	was	
possible	to	remove	the	benzyl	protecting	group	by	hydrogenation	with	palladiumII	chloride,	before	
trifluoroacetic	acid	(TFA)	was	used	to	remove	the	Boc	protecting	group	and	acetal	to	afford	the	
deprotected	product	89	in	a	crude	73%	yield	(scheme	21).	As	the	benzyl	protecting	group	required	
an	extra	deprotection	step,	and	the	methyl	ester	removal	conditions	were	unlikely	to	be	compatible	
with	the	oxazoline	ring,	it	was	decided	to	progress	the	synthesis	using	TMSE	protected	right	hand	
side	84.	
	
Scheme	21.	Model	system	to	investigate	end	game.	Reagents	and	conditions:	a)	LiOH,	MeOH/H2O,	
0	°C	-	rt,	19	h;	b)	anhydrous	HCl,	1,4-dioxane,	0	°C	–	rt,	30	min;	c)	HATU,	NiPr2Et,	CH2Cl2/DMF,	0	°C	–	
rt,	19	h,	38%;	d)	Deoxo-Fluor®,	CH2Cl2,	-20	°C,	1	h,	74%;	e)	i.	PdCl2,	H2,	MeOH,	2	h,	ii.	TFA,	CH2Cl2,	6	h,	
73%	(crude	yield).	
	
Coupling	and	completion	of	plantazolicin	A	and	B.	The	coupling	and	cyclization	conditions	
established	using	the	model	were	then	applied	to	the	prepared	plantazolicin	coupling	partners	54,	
55	and	84	to	afford	the	protected	natural	products	90	and	91.	Pleasingly,	it	was	found	that	treating	
these	with	neat	TFA	led	to	the	removal	of	all	protecting	groups,	as	long	as	care	was	taken	to	exclude	
water	to	avoid	the	hydrolysis	of	the	oxazoline	ring	(scheme	22).	Purification	was	carried	out	using	
HPLC	and	full	comparison	of	synthetic	and	natural	plantazolicin	A	is	included	in	our	communication	
of	this	work[10]	and	Moody’s	synthesis	of	plantazolicin	A[6]	included	a	HPLC	comparison	of	their	
synthetic	1	to	material	synthesised	by	this	route.	To	the	best	of	our	knowledge	the	characterisation	
of	biosynthetic	precursor	plantazolicin	B	(2)	has	not	been	carried	out	elsewhere.	
	
Scheme	22.	Synthesis	of	plantazolicin	A	(1)	and	B	(2).	Reagents	and	conditions:	a)	LiOH,	THF/H2O,	
0	°C,	2	h	25	min;	b)	anhydrous	HCl,	1,4-dioxane,	0	°C	–	rt,	30	min;	c)	HATU,	NiPr2Et,	CH2Cl2/DMF,	0	°C	
-	rt,	16	h;	d)	Deoxo-Fluor®,	CH2Cl2,	-20	°C,	24	h	(90)/17	h	(91),	90	=	43%,	91	=	35%;	e)	TFA,	rt,	2	h	(1)/	
1h	(2),	1	=	59%,	2	=	64%.	
	
Conclusions	
A	comprehensive	account	of	our	investigations	into	the	total	syntheses	of	polyazole	peptide	natural	
product	plantazolicin	A,	and	its	biosynthetic	precursor	plantazolicin	B	has	been	disclosed.	The	
preparation	of	the	challenging	arginine	derived	thiazole	fragments	was	achieved	from	natural	amino	
acids	and	proved	to	be	readily	scalable.	The	synthesis	of	a	variety	of	differently	protected	key	
fragments	led	to	the	development	of	an	efficient	overall	protecting	group	strategy.	Furthermore,	the	
implementation	of	simultaneous	cyclizations/oxidations	allowed	the	convergent	assembly	of	the	
polyoxazole	subunits,	leading	to	a	step	economic	highly	convergent	overall	synthesis	of	both	
plantazolicin	A	and	B.		
Experimental	Section	
Complete	experimental	details	and	characterisation	for	all	compounds	described	in	this	manuscript	
can	be	found	in	the	supporting	information.	Additional	data	related	to	this	publication	is	available	at	
the	University	of	Cambridge	Institutional	Data	Repository	(http://dx.doi.org/10.17863/CAM.486).	
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